# Prediction Model fo Screening and Diagnosis of Prostate Cancer in PSA Gray Zone Based on Serum PHI Combined With TPV

> **NCT04251546** · — · UNKNOWN · sponsor: **Xinhua Hospital, Shanghai Jiao Tong University School of Medicine** · enrollment: 80 (estimated)

## Conditions studied

- Prostate Cancer
- PSA

## Interventions

- **DIAGNOSTIC_TEST:** p2PSA
- **DIAGNOSTIC_TEST:** Ultrasonic parameters
- **DIAGNOSTIC_TEST:** Transperineal prostate biopsy

## Key facts

- **NCT ID:** NCT04251546
- **Lead sponsor:** Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-01-04
- **Primary completion:** 2022-09-30
- **Final completion:** 2022-09-30
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2022-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04251546

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04251546, "Prediction Model fo Screening and Diagnosis of Prostate Cancer in PSA Gray Zone Based on Serum PHI Combined With TPV". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04251546. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*